Aura Biosciences Inc (AURA) Stock Analysis
Verdict: HOLD
Aura's Phase 3 candidate in ocular oncology offers high upside, but $85M annual cash burn creates dilution risk before 2028 revenue.
Investment score: 46/100
Analysis as of
Is Aura Biosciences Inc stock worth reviewing? AI model thesis
AURA is a pre-revenue clinical biopharma holding $149.74M in current assets with $85.2M annual burn (~21 months cash runway), facing pivotal Phase 3 AU-011 trial milestones.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Aura Biosciences Inc opportunities and risks
What speaks for AURA
- Flagship asset AU-011 addresses an unmet medical need in primary choroidal melanoma with orphan drug designation.
What speaks against AURA
- Persistent operational cash burn risks medium-term shareholder dilution.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -14.9% |
| NVCT | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| IRWD | 5.5x | 1.8x | 4.3x | 99.8% | 33.4% | 25.9% |
| NGNE | n/a | 0.0x | n/a | 0.0% | 0.0% | -16.0% |
| MNPR | n/a | 0.0x | n/a | 0.0% | 0.0% | -485.3% |
| MDXG | 118.1x | 1.9x | 23.4x | 78.8% | 1.8% | 5.9% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
Frequently asked questions about Aura Biosciences Inc (AURA)
Is AURA stock a good investment?
The cached TradeMates AI model rates Aura Biosciences Inc as HOLD with an investment score of 46/100. AURA is a pre-revenue clinical biopharma holding $149.74M in current assets with $85.2M annual burn (~21 months cash runway), facing pivotal Phase 3 AU-011 trial milestones. This is algorithmic model output, not personal investment advice.
Is AURA stock a buy?
The TradeMates model verdict for AURA is HOLD with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.